Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery

Journal of Pharmaceutical Sciences

Volumn 99, Issue 4, 2010, Pages 2049-2060

  Bayindir, Zerrin Sezgin ^a   Yuksel, Nilufer ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Encapsulation efficiency; Formulation; Gastrointestinal enzymes; Niosomes; Oral drug delivery; Paclitaxel; Particle size; Stability; Surfactants; Zeta potential

Indexed keywords

BRIJ 72; BRIJ 76; CHYMOTRYPSIN; NIOSOME; NONIONIC SURFACTANT; PACLITAXEL; PEPSIN A; POLYMER; POLYOXYETHYLENE STEARYL ETHER; POLYSORBATE 20; POLYSORBATE 60; SORBITAN LAURATE; SORBITAN PALMITATE; SORBITAN STEARATE; TRYPSIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG STORAGE; ENCAPSULATION; HYDRATION; PARTICLE SIZE; STRUCTURE ANALYSIS; SURFACE CHARGE; ZETA POTENTIAL;

EID: 77949828159     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21944     Document Type: Article

References (49)

1. Panchagnula R. 1998. Pharmaceutical aspects of Paclitaxel. Int J Pharm 172:1-15.
2. Arica Yegin B, Benoît JP, Lamprecht A. 2006. Paclitaxel-loaded lipid nanoparticles prepared by solvent injection or ultrasound emulsification. Drug Dev Ind Pharm 32:1089-1094.
3. Choi JS, Jo BW. 2004. Enhanced paclitaxel bio-availability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. Int J Pharm 280:221-227.
4. Lee SY, Hyun H, Youn JY, Kim BS, Song IB, Kim MS, Lee B, Khang G, Lee HB. 2008. Preparation of nano-emulsified paclitaxel using MPEG-PLGA diblock copolymers. Coll Surf A: Physicochem Eng Aspects 313-314:126-130.
5. Nornoo AO, Osborne DW, Chow DS. 2008. Cremophor-free intravenous microemulsions for paclitaxel I: Formulation, cytotoxicity and hemolysis. Int J Pharm 349:108-116.
6. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S, Seo MH. 2001. In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy. J Cont Rel 72:191-202.
7. Liggins RT, Hunter WL, Burt HM. 1997. Solid-state characterization of paclitaxel. J Pharm Sci 86: 1458-1463.
8. Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, Ahmad I. 2005. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm 59:177-187.
9. Veltkamp SA, Thijssen B, Garrigue JS, Lambert G, Lallemand F, Binlich F, Huitema AD, Nuijen B, Nol A, Beijnen JH, Schellens JH. 2006. A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. Br J Cancer 95:729-734.
10. Peltier S, Oger JM, Lagarce F, Couet W, Benoît JP. 2006. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res 23:1243-1250.
11. Dabholkar RD, Sawant RM, Mongayt DA, Devarajan PV, Torchilin VP. 2006. Polyethylene glycolphosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: Some properties, loading with paclitaxel, and modulation of P-glycoproteinmediated efflux. Int J Pharm 315:148-157.
12. Bilensoy E, Gürkaynak O, Doǧan AL, Hincal AA. 2008. Safety and efficacy of amphiphilic beta-cyclodextrin nanoparticles for Paclitaxel delivery. Int J Pharm 347:163-170.
13. Hu FQ, Ren GF, Yuan H, Du YZ, Zeng S. 2006. Shell cross-linked stearic acid grafted chitosan oligosaccharide self-aggregated micelles for controlled release of paclitaxel. Coll Surf B Bioint 50:97-103.
14. Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD. 2007. Enhanced solubility and stability of PEGylated liposomal paclitaxel: In vitro and in vivo evaluation. Int J Pharm 338:317-326.
15. Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, Shim CK, Kim DD. 2007. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Cont Rel 120:169-177.
16. Fan T, Takayama K, Hattori Y, Maitani Y. 2004. Formulation optimization of paclitaxel carried by PEGylated emulsions based on artificial neural network. Pharm Res 21:1692-1697.
17. Dong Y, Zhang Z, Feng SS. 2008. D-a-Tocopheryl polyethylene glycol 1000 succinate (TPGS) modified poly(l-lactide) (PLLA) films for localized delivery of paclitaxel. Int J Pharm 350:166-171.
18. Lim Soo P, Cho J, Grant J, Ho E, Piquette-Miller M, Allen C. 2008. Drug release mechanism of paclitaxel from a chitosan-lipid implant system: Effect of swelling, degradation and morphology. Eur J Pharm Biopharm 69:149-157.
19. Win KY, Feng S. 2005. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26:2713-2722.
20. Zhang Z, Feng SS. 2006. Self-assembled nanoparticles of poly(lactide)-Vitamin E TPGS copolymers for oral chemotherapy. Int J Pharm 324:191-198.
21. Veltkamp SA, Rosing H, Huitema AD, Fetell MR, Nol A, Beijnen JH, Schellens JH. 2007. Novel paclitaxel formulations for oral application: A phase I pharmacokinetic study in patients with solid tumours. Cancer Chemother Pharmacol 60:635-642.
22. Dong Y, Feng SS. 2007. Poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles prepared by high pressure homogenization for Paclitaxel chemotherapy. Int J Pharm 342:208-214.
23. Chen H, Langer R. 1998. Oral particulate delivery: Status and future trends. Adv Drug Del Rev 34: 339-350.
24. Pardakhty A, Varshosaz J, Rouholamini A. 2007. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J Pharm 328:130-141.
25. Uchegbu IF, Florence AT. 1995. Non-ionic surfactant vesicles (niosomes): Physical and pharmaceutical chemistry. Adv Coll Int Sci 58:1-55.
26. Varshosaz J, Pardakhty A, Hajhashemi VI, Najafabadi AR. 2003. Development and physical characterization of sorbitan monoester niosomes for insulin oral delivery. Drug Del 10:251-262.
27. Manosroi A, Wongtrakul P, Manosroi J, Sakai H, Sugawara F, Yuasa M, Abe M. 2003. Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol. Coll Surf B: Bioint 30:129-138.
28. Pillai GK, Salim ML. 1999. Enhanced inhibition of platelet aggregation in-vitro by niosome-encapsulated indomethacin. Int J Pharm 193:123-127.
29. Girigoswami A, Das S, De S., 2006. Fluorescence and dynamic light scattering studies of niosomesmembrane mimetic systems. Spectrochim Acta A: Mol Biomol Spectrosc 64:859-866.
30. Uchegbu IF, Vyas SP. 1998. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 172:33-70.
31. Uchegbu IF. 2000. Niosomes and other synthetic surfactant vesicles with anti-tumour drugs. In: Uchegbu IF, editor. Synthetic surfactant vesicles. 1st edition. Netherlands: Harwood Academic Publishers. pp. 115-134.
32. Pardakhty A, Varshosaz J, Rouholamini A. 2007. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J Pharm 328:130-141.
33. Sezgin Z, Yü ksel N, Baykara T. 2006. Preparation and characterization of polymeric micelles for solubilization of poorly soluble anticancer drugs. Eur J Pharm Biopharm 64:261-268.
34. Official Website. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Available at: http://www.ich.org. Accessed January 21, 2009.
35. Abdelbary G, El-Gendy N. 2008. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech 9:740-747.
36. Kaur K, Jain S, Sapra B, Tiwary AK. 2007. Niosomal gel for site-specific sustained delivery of antiarthritic drug: In vitro-in vivo evaluation. Curr Drug Del 4:276-282.
37. Wagner JP. 1971. Biopharmaceutics and relevant pharmacokinetics. IL, USA: Drug Intelligence Publications. pp. 115-118.
38. Yuksel N, Kanik AE, Baykara T. 2000. Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and -independent methods. Int J Pharm 209:57-67.
39. Paolino D, Cosco D, Muzzalupo R, Trapasso E, Picci N, Fresta M. 2008. Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. Int J Pharm 353: 233-242.
40. McMullen TP, McElhaney RN. 1997. Differential scanning calorimetric studies of the interaction of cholesterol with distearoyl and dielaidoyl molecular species of phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine. Biochemistry 36:4979-4986.
41. Devaraj GN, Parakh SR, Devraj R, Apte SS, Rao BR, Rambhau D. 2002. Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. J Coll Int Sci 251:360-365.
42. Uchegbu IF, Duncan R. 1997. Niosomes containing N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin (PK1): Effect of method of preparation and choice of surfactant on niosome characteristics and a preliminary study of body distribution. Int J Pharm 155:7-17.
43. Mura S, Pirot F, Manconi M, Falson F, Fadda AM. 2007. Liposomes and niosomes as potential carriers for dermal delivery of minoxidil. J Drug Target 15: 101-108.
44. Xie J, Wang CH. 2004. Paclitaxel-loaded biodegradable nanoparticles developed by direct dialysis and electrodydrodynamic atomization methods. AIChE Annual Meeting.
45. Martin A. 1993. Physical pharmacy. 4th edition. MD, USA: Lippincolt Williams & Wilkins. p. 410.
46. Nornoo AO, Chow DS. 2008. Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. Int J Pharm 349:117-123.
47. Manconi M, Sinico C, Valenti D, Lai F, Fadda AM. 2006. Niosomes as carriers for tretinoin. III. A study into the in vitro cutaneous delivery of vesicle-incorporated tretinoin. Int J Pharm 311:11-19.
48. Guinedi AS, Mortada ND, Mansour S, Hathout RM. 2005. Preparation and evaluation of reversephase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm 306:71-82.
49. Mahato RI, Narang AS, Thoma L, Miller DD. 2003. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 20:153-214.